Amplification of the human gene MYCN may play a role in the malignant progression of human neuroblastomas. In pursuit of this possibility, previous studies have shown that the abundant expression of MYCN in cultured cells can elicit several aspects of the transformed phenotype. We now extend those findings by demonstrating that rat embryo cells transfected with MYCN can proliferate for at least 200 generations. Isolation of established cells was dependent on high expression of MYCN and on biological selection to eliminate untransfected cells. The established cells were not tumorigenic in syngeneic rats or athymic mice, failed to grow in soft agar, and required relatively high concentrations of serum for proliferation in culture. Our results show that enhanced expression of MYCN can rescue normal cells from senescence, add to the credentials of MYCN as an authentic protooncogene, and identify an additional biological activity that can be used in the characterization of MYCN.
MYCN was discovered during surveys of human neuroblastoma cells containing karyotypic manifestations of amplified cellular DNA (1, 2). The gene is amplified most commonly in human neuroblastomas, but also in some specimens from small-cell lung cancers (3) , retinoblastomas (4) and astrocytomas (5) . These findings prompted the suggestion that enhanced expression ofM YCN might contribute to malignant progression of certain neuroectodermal tumors (6) . The most consistent picture has emerged for neuroblastoma, in which amplification of MYCN is associated with roughly 50% of advanced-stage tumors (7) and indicates poor prognosis (8) . This correlation between amplification of MYCN and tumor stage and the observed high expression of MYCN in poorly differentiated cells (6, (9) (10) (11) (12) (13) suggest that enhanced expression of MYCN consequent to amplification contributes to tumor progression.
Identification of MYCN was facilitated by its resemblance to the protooncogene MYC (1, 2, 14, 15) . Both MYCN and MYC comprise three exons and two intervening sequences (14, 15) and encode nuclear phosphoproteins of similar size that bind to DNA in vitro (16, 17) . These similarities raised the possibility that MYCN may be an authentic protooncogene, capable of contributing to the transformation of cells and to tumorigenesis.
The oncogenic potential of MYCN has been addressed experimentally in cultured cells by using vectors that drive the expression of M YCN with a promoter and enhancer from the U3 region of the long terminal repeat (LTR) of Moloney murine leukemia virus (Mo-MuLV). The results showed that augmented expression ofMYCN induces tumorigenicity in an established line of rat fibroblasts (Rat-1 cells) (18) and can assist a mutant allele of the protooncogene HRAS in the transformation of rat embryo cells (19, 20) . We now extend these characterizations by showing that the solitary action of MYCN can establish the sustained proliferation of earlypassage rat embryo cells. Our findings reinforce the image of MYCN as a multipotent oncogene and sustain the view that anomalous expression of the gene might contribute to tumorigenesis.
MATERIALS AND METHODS
Molecular Clones. We used three vectors containing alleles of MYCN: pMP-34.1K, containing MYCN isolated from the Kelly line of human neuroblastoma cells; pMP-34.1N, containing MYCN from the leukocytes of a normal individual; and pMP-34.1KXho, containing a mutant allele of MYCN with a termination codon in the first coding exon (19) . In these vectors, transcription is driven by the U3 region in the LTR of Mo-MuLV (see Fig. 1 and ref. 19 ). The MYC expression vector pHSR-1(LTR) contains the U3 and R regions of the Mo-MuLV LTR linked to a normal allele of MYC (see Fig. 1 and refs. 21 and 22). Molecular clone pCV108 contains the bacterial neomycin-resistance gene fused to a Mo-MuLV LTR (gift from Chris Lau, University of California, San Francisco).
Transfection and Selection of Cells in Culture. Primary cultures of rat embryo cells were prepared from 12-to 14-day-old Fisher rat embryos. After 2-4 days of growth in Dulbecco's modified Eagle's (DME) medium supplemented with 10% (vol/vol) fetal calf serum and antibiotics, the cells were seeded at a density of 1 x 106 per 100-mm dish. Transfections were performed with 75 ,ug of carrier DNA from salmon sperm plus 15 ug of circular MYCN or MYC vector DNA and 1 ,ug of pCV108 DNA for two dishes, each containing about 4 x 106 cells at the time of transfection. Approximately 24 hr after transfection, the cells were passaged at a ratio of 1:3. Selection was done in medium containing 400 jig of crude G 418 (GIBCO) per ml.
Assay for Colony Formation in Soft Agarose. For analyses of anchorage-independent growth, 5 x 104 cells were suspended in 5 ml of 0.35% low-melting-point agarose (Sea Plaque) and seeded into 60-mm culture dishes containing a 0.7% agarose base. All agarose suspensions were made in DME medium containing 10% fetal calf serum. Plates were inspected by microscopy at regular intervals for 3 weeks.
Assay for Tumorigenicity. Analyses for tumorigenicity were done by subcutaneously injecting 5 x 106 cells in 0.5 ml of DME medium into 28- M CsCl2/0.1 M EDTA, pH 7.0, and centrifuged in an SW 41.1 rotor (Beckmann) at 38,000 rpm for 15 hr. DNA was recovered from the viscous interphase, dialyzed against 100 mM NaCl/1 mM EDTA, pH 7.0, treated with proteinase K, extracted with phenol, and precipitated with ethanol. Polyadenylylated RNA was isolated from total RNA by chromatography through oligo(dT)-cellulose.
Analysis of DNA and RNA. DNA was cut with the appropriate restriction endonuclease, fractionated on an agarose gel, transferred to nitrocellulose paper, and hybridized with the 32P-labeled insert of the MYCN clone pNB-1 (1). RNA was fractionated on agarose gels in the presence of 2.2 M formaldehyde and further analyzed as for DNA.
RESULTS
Establishment of Rat Embryo Cells in Culture by MYCN. In an attempt to establish long-term cultures ofearly-passage rat embryo cells, we transfected the cells with the MYCN expression vector pMP-34.1K (Fig. 1) . The cells were then passaged at a ratio of 1:3 twice a week and regularly inspected for more than 40 generations. We could not recover any cells that showed signs of proliferation after this period of time.
Reasoning that normal cells in the cultures might inhibit the proliferation of transfected cells expressing MYCN (23), we then used an alternative strategy. Cells were cotransfected with the MYCN expression vector and with the plasmid pCV108 conferring G418 resistance. Approximately 48 hr later, G418 (400 ,g/ml) was added to the culture medium, and the cells were then maintained in the selection medium. Two weeks after transfection, colonies of G418-resistant cells were clearly visible. Cells from seven colonies were picked from the plate and transferred to microtiter plates. All seven foci could be established in long-term culture for more than 200 generations without indications of senescence. The doubling time of the established cells was comparable to that of an established line of rat cells (Rat-1).
To test whether establishment resulted from expression of MYCN, we introduced into rat embryo cells a combination of pCV108 and an MYCN vector containing a frameshift mutation within the second exon of MYCN. None of the selected clones could be established in long-term culture. These results showed that the establishment of rat embryo cells depended on expression of MYCN protein.
For comparison, we also transfected rat embryo cells with the MYC expression vector pHSR-1(LTR). After cotransfection with a selectable marker and subsequent culture in selection medium, we again obtained colonies of cells. Ten of these were isolated; all 10 proliferated into long-term cultures.
The cells established in culture by MYCN or MYC displayed a fusiform morphology (Fig. 2W) , differing from the less refractile, flat morphology of cells into which mutant MYCN (Fig. 2M) or only plasmid pCV108 (Fig. 2C) Proc. Natl. Acad. Sci. USA 85 (1988) 3 from all seven clones established after MYCN transfection were cut with the restriction endonuclease EcoRI and analyzed by electrophoresis in agarose. For the molecular probe, we used the EcoRI-BamHI insert of plasmid pNb-1 (1), which detects a 2.0-kilobase-pair (kbp) EcoRI fragment in human DNA and an approximately 12-kbp EcoRI fragment in rat DNA (Fig. 3, lanes H and R, respectively) . Inspection of the autoradiograph indicated that clones 1-7 carried from 5 to 50 copies of human MYCN sequences in addition to the endogenous MYCN of the rat. Clone 3 apparently carried the lowest number of copies, and clone 6, the highest number. For comparison, human neuroblastoma line Kelly (Fig. 3,  lane N) contained approximately 120 copies of MYCN (1, 6) . The additional faint bands in DNA of clones 1-7 presumably represented rearrangements of exogenous MYCN in the transfected cells. The additional strong band at ca. 6 kbp was most likely due to the vector sequences detected by plasmid DNA present within the molecular probe.
Analysis of polyadenylylated RNA detected (i) the anticipated 2.8-kb MYCN mRNA in the Kelly line of neuroblastoma cells that carry ca. 120 copies ofMYCN (Fig. 4, lane N) , (ii) the comparable RNA in the seven clones of cells established after transfection with MYCN (Fig. 4, lanes 1-7) , and (iii) no MYCN RNA in normal rat embryo cells (Fig. 4, To define in more detail to what degree the rat embryo cells established in culture were dependent on serum for proliferation, we grew cells in the presence of different concentrations of fetal calf serum. Approximately 5 x 106 cells from all seven clones were seeded into 100-mm plates in 10% fetal calf serum. Approximately 15 hr later, the medium on replica plates was replaced with fresh medium containing 10%, 5%, 2%, or 0.5% fetal calf serum. Plates were inspected after 72 hr. There was no obvious difference in morphology of cells grown in 10%, 5%, or 2% fetal calf serum, although the population density at 2% was clearly lower than at 5% or 10% (Fig. 5) (18) (19) (20) , and they sustain the view that the abnormally high expression of an otherwise normal allele of MYCN contributes to the neoplastic phenotype of the neuroblastomas in which the gene is amplified.
Rat embryo cells can be established in culture by a variety of protooncogenes and oncogenes, including MYC (23, 24) , v-myc (23) (24) (25) , polyomavirus tsa encoding the large tumor antigen (26) , TP53 encoding tumor protein p53 (27) , and adenovirus Ela (24) . In the work reported here, all clones isolated after transfection with either MYCN or MYC proliferated into long-term cultures. We conclude that these two genes do not differ appreciably in their ability to sustain the proliferation of embryonic cells-a conclusion that conforms to the extensive resemblance between the proteins encoded by MYC and MYCN (16, 17 (23) .
Amplification of MYCN as a Step in Tumorigenesis. Malignant tumors characteristically arise from a multiplicity of events within the emerging cancer cell. Prominent among these events are various forms of genetic damage, which may contribute to both the initiation and the continued progression of tumorigenesis (32 (ii). Amplification of MYCN has been found only in the more aggressive variants of human neuroblastoma (7) , where it connotes a dire prognosis (8) . These findings prompted the hypothesis that anomalous expression of MYCN is a late event in the genesis of neuroblastomas, contributing to malignant progression of the tumors. The ability of MYCN to convert established rodent cells to a tumorigenic phenotype conforms to (but by no means proves) this hypothesis (18) .
We conclude that it is presently impossible to assign MYCN a specific role in tumorigenesis. But the results presented here enhance the credentials of MYCN as an authentic protooncogene, provide an additional biological parameter for use in the characterization of MYCN and suggest that MYCN may be useful for the establishment of cell lines from various embryonic lineages.
